Skip to content
Screener

Solid Biosciences Inc. SLDB Q2 2026 earnings

Reported August 6, 2026 · After market close

EPS-$0.38Beat by $0.08
EPS estimate-$0.46

Next report

Nov 2, 2026 (in a month)
EPS estimate-$0.37

Financials

Q2 2026

Income statement

See full
Operating income-$57.4M-37.6%
Net income-$54.8M-38.8%
EPS (diluted)-$0.38+9.5%

Balance sheet

See full
Cash & equivalents$159.4M+14.7%
Total debt$20.2M-12.6%
Total equity$374.1M+44.8%
Total assets$420.6M+36.4%

Cash flow

See full
Operating cash flow-$52.6M-40.6%
CapEx$150.0K-60.2%
Free cash flow-$52.7M-39.6%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$935M+120%
Enterprise value$795.77M+157%

Returns & leverage

See full
Return on equity-65.5%-2.5pp
Debt / equity0.1×0.0×
Current ratio13.8×+4.5×

FAQ

When did Solid Biosciences Inc. report Q2 2026 earnings?
Solid Biosciences Inc. (SLDB) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Solid Biosciences Inc.'s Q2 2026 revenue and EPS?
Solid Biosciences Inc. reported eps of $-0.38 for Q2 2026.
Did Solid Biosciences Inc. beat estimates in Q2 2026?
EPS beat the consensus estimate of $-0.46 by $0.08.
How did Solid Biosciences Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 9.5% from $-0.42.
Where can I find Solid Biosciences Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-338438) and the 10-Q periodic report (0001193125-26-337935) directly on SEC EDGAR. The filing index links above go to sec.gov.